Dataene vedrørende brug af gemfibrozil sammen med de øvrige statiner indikerer også en øget risiko, men misforholdet mellem indberetningsfrekvensen ved kombinationsbehandling og antallet af recepter er betydeligt mindre end ved cerivastatin.
The data for use of gemfibrozil with the other statins also suggest an increased risk however the disproportion between the reporting rate on combination treatment and the proportion of prescriptions is considerably less than that seen with cerivastatin.